Oppenheimer analyst Matthew Biegler says Blueprint Medicines (BPMC) reported Q4 Ayvakit sales of $146M, in line with consensus but below the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback